NCT01590199View on ClinicalTrials.gov

Evaluate Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

May 18, 2012

Primary Completion Date

September 11, 2018

Study Completion Date

September 11, 2018

Conditions
Neuroendocrine Tumors
Interventions
DRUG

RAD001

DRUG

SOM230

Trial Locations (3)

13353

Novartis Investigative Site, Berlin

48149

Novartis Investigative Site, Münster

99438

Novartis Investigative Site, Bad Berka

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY